These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29217691)

  • 1. First-Line Osimertinib Beneficial in Advanced NSCLC.
    Cancer Discov; 2018 Jan; 8(1):OF1. PubMed ID: 29217691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
    Kuiper JL; Heideman DA; Würdinger T; Grünberg K; Groen HJ; Smit EF
    Clin Lung Cancer; 2015 Jan; 16(1):60-6. PubMed ID: 25242669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
    Vergnenegre A; Massuti B; de Marinis F; Carcereny E; Felip E; Do P; Sanchez JM; Paz-Arez L; Chouaid C; Rosell R;
    J Thorac Oncol; 2016 Jun; 11(6):801-7. PubMed ID: 26899757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osimertinib.
    Malapelle U; Ricciuti B; Baglivo S; Pepe F; Pisapia P; Anastasi P; Tazza M; Sidoni A; Liberati AM; Bellezza G; Chiari R; Metro G
    Recent Results Cancer Res; 2018; 211():257-276. PubMed ID: 30069773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Liao BC; Lin CC; Lee JH; Yang JC
    Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
    Gao G; Ren S; Li A; Xu J; Xu Q; Su C; Guo J; Deng Q; Zhou C
    Int J Cancer; 2012 Sep; 131(5):E822-9. PubMed ID: 22161771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
    Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
    Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use.
    Scott LJ
    Drugs Ther Perspect; 2019; 35(1):50. PubMed ID: 31186615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression.
    Abdayem P; Planchard D
    Transl Lung Cancer Res; 2020 Oct; 9(5):2165-2172. PubMed ID: 33209637
    [No Abstract]   [Full Text] [Related]  

  • 12. Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.
    Popat S
    N Engl J Med; 2018 Jan; 378(2):192-193. PubMed ID: 29320658
    [No Abstract]   [Full Text] [Related]  

  • 13. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.
    Goss G; Tsai CM; Shepherd FA; Ahn MJ; Bazhenova L; Crinò L; de Marinis F; Felip E; Morabito A; Hodge R; Cantarini M; Johnson M; Mitsudomi T; Jänne PA; Yang JC
    Ann Oncol; 2018 Mar; 29(3):687-693. PubMed ID: 29293889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third generation EGFR TKIs: current data and future directions.
    Tan CS; Kumarakulasinghe NB; Huang YQ; Ang YLE; Choo JR; Goh BC; Soo RA
    Mol Cancer; 2018 Feb; 17(1):29. PubMed ID: 29455654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.
    Gettinger SN; Wurtz A; Goldberg SB; Rimm D; Schalper K; Kaech S; Kavathas P; Chiang A; Lilenbaum R; Zelterman D; Politi K; Herbst RS
    J Thorac Oncol; 2018 Jun; 13(6):831-839. PubMed ID: 29578107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological and immunophenotypical differences between chronic periodontitis and peri-implantitis - a cross-sectional study.
    Galindo-Moreno P; López-Martínez J; Caba-Molina M; Ríos-Pelegrina R; Torrecillas-Martínez L; Monje A; Mesa F; Chueca N; García-García F; O'Valle F
    Eur J Oral Implantol; 2017; 10(4):453-463. PubMed ID: 29234752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current treatment of double hit and double expressor lymphoma.
    Reagan PM; Davies A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):295-297. PubMed ID: 29222269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Management of a Child With Drug-induced Necrotizing Pancreatitis During Acute Lymphoblastic Leukemia Therapy: A Case Report.
    Płotka A; Wziątek A; Wachowiak J; Derwich K
    J Pediatr Hematol Oncol; 2019 Mar; 41(2):e125-e128. PubMed ID: 29683955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia.
    Chen N; Feng L; Qu H; Lu K; Li P; Lv X; Wang X
    Oncol Rep; 2018 Jun; 39(6):3064-3072. PubMed ID: 29658610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-terminal binding protein‑2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis.
    Shi H; Mao Y; Ju Q; Wu Y; Bai W; Wang P; Zhang Y; Jiang M
    Int J Oncol; 2018 Jul; 53(1):167-176. PubMed ID: 29658564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.